Pfizer said late Wednesday it has been told by regulators that the data submitted in its application for the use of its drug Lyrica as a stand-alone treatment for generalized anxiety disorder were insufficient to gain approval. The Food and Drug Administration's decision came after Pfizer (PFE) resubmitted its application in response to a "not-approvable" letter issued by the FDA in August 2004. The FDA is still reviewing a separate application